Literature DB >> 21264196

Seniors with Parkinson's disease: initial medical treatment.

J Eric Ahlskog1.   

Abstract

Parkinson's disease most often presents after age 60, and patients in this age group are best managed with levodopa therapy as the primary treatment modality. Unlike young-onset parkinsonism (onset <age 40), this older age group is much less prone to subsequent development of levodopa responsive instability (dyskinesias, fluctuations). When these problems do occur in seniors, they usually can be managed by medication adjustments. The treatment goal is to keep patients active and engaged; levodopa dosage should be guided by the patients' responses and not arbitrarily limited to low doses, which may compromise patients' lives.

Entities:  

Keywords:  Parkinson's disease; dopamine agonists; dyskinesias; levodopa

Year:  2010        PMID: 21264196      PMCID: PMC3024520          DOI: 10.3988/jcn.2010.6.4.159

Source DB:  PubMed          Journal:  J Clin Neurol        ISSN: 1738-6586            Impact factor:   3.077


  84 in total

1.  Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease.

Authors:  H I Hurtig; J Q Trojanowski; J Galvin; D Ewbank; M L Schmidt; V M Lee; C M Clark; G Glosser; M B Stern; S M Gollomp; S E Arnold
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

2.  Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

Authors:  G Block; C Liss; S Reines; J Irr; D Nibbelink
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

3.  Mortality of patients with Parkinson's disease treated with levodopa.

Authors:  R J Marttila; U K Rinne; T Siirtola; V Sonninen
Journal:  J Neurol       Date:  1977-10-07       Impact factor: 4.849

4.  Prevalence of repetitive and reward-seeking behaviors in Parkinson disease.

Authors:  V Voon; K Hassan; M Zurowski; M de Souza; T Thomsen; S Fox; A E Lang; J Miyasaki
Journal:  Neurology       Date:  2006-09-06       Impact factor: 9.910

Review 5.  Slowing Parkinson's disease progression: recent dopamine agonist trials.

Authors:  J Eric Ahlskog
Journal:  Neurology       Date:  2003-02-11       Impact factor: 9.910

6.  Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons.

Authors:  Heiko Braak; Magdalena Sastre; Jürgen R E Bohl; Rob A I de Vos; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2007-02-09       Impact factor: 17.088

7.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

8.  Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality.

Authors:  A Schrag; Y Ben-Shlomo; R Brown; C D Marsden; N Quinn
Journal:  Mov Disord       Date:  1998-11       Impact factor: 10.338

Review 9.  The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.

Authors:  S Fahn; G Cohen
Journal:  Ann Neurol       Date:  1992-12       Impact factor: 10.422

10.  Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy.

Authors:  Andrew McKeon; Keith A Josephs; Kevin J Klos; Kathleen Hecksel; James H Bower; J Michael Bostwick; J Eric Ahlskog
Journal:  Parkinsonism Relat Disord       Date:  2007-06-04       Impact factor: 4.891

View more
  2 in total

1.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

Review 2.  Patterns and Determinants of Prescribing for Parkinson's Disease: A Systematic Literature Review.

Authors:  Khalid Orayj; Emma Lane
Journal:  Parkinsons Dis       Date:  2019-11-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.